Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence

Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697) .

(2017) S. S. Agarwala et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.

(2017) Philippa Corrie et al.   JOURNAL OF CLINICAL ONCOLOGY

Surgery for Distant Melanoma Metastasis

(2012) Anna M. Leung et al.   CANCER JOURNAL

Outcome following local recurrence or in-transit metastases in cutaneous melanoma

(2012) Nora J. Suojärvi et al.   MELANOMA RESEARCH

A randomised phase II trial of 1month versus 1year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients

(2011) Lili Mao et al.   EUROPEAN JOURNAL OF CANCER

Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991

(2011) Alexander M.M. Eggermont et al.   EUROPEAN JOURNAL OF CANCER

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis

(2010) S. Mocellin et al.   JNCI-Journal of the National Cancer Institute

Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma

(2009) Dimitrios Pectasides et al.   JOURNAL OF CLINICAL ONCOLOGY